Surmodics, Inc. reiterated earnings guidance for the year 2022. For the year, the company expects revenue to range from $97 million to $101 million. Diluted GAAP EPS is expected to range from a loss per share of $2.05 to $1.55, which reflects increased investments to accelerate the Company's strategy.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.84 USD | -0.05% | -0.31% | +15.10% |
10/06 | Surmodics Signs Group Purchasing Deal With Premier | MT |
30/05 | Barrington Research Downgrades SurModics to Market Perform From Outperform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.10% | 597M | |
-3.76% | 187B | |
+0.19% | 109B | |
-2.94% | 69.22B | |
-6.16% | 46.36B | |
+13.62% | 46.19B | |
+8.48% | 42.44B | |
+18.20% | 30.84B | |
+19.69% | 25.73B | |
-9.24% | 23.3B |
- Stock Market
- Equities
- SRDX Stock
- News Surmodics, Inc.
- Surmodics, Inc. Reiterates Earnings Guidance for the Year 2022